Genmab vs ResMed
Genmab (GMAB), health care, and ResMed (RMD), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
ResMed is worth $33.5B on the stock market and Genmab $32B: ResMed is valued at 4% more. Genmab trades at 44.4 times earnings and ResMed at 21.7; operating margins in their latest fiscal years were 28.6% and 33.4%. Over the past year Genmab's share price has moved +70.1% and ResMed's -3.26%.
Key facts
- Genmab market value
- $32B
- ResMed market value
- $33.5B
- Genmab P/E
- 44.4
- ResMed P/E
- 21.7
- Genmab revenue
- $3.7BFY to 2025-12-31
- ResMed revenue
- $5.7BFY to 2026-06-30
- Superinvestors holding both
- 0
Market values as of .
| Measure | Genmab | ResMed |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2026-06-30 |
| Size | ||
| Market cap | $32Blower | $33.5Bhigher |
| Revenue | $3.7Blower | $5.7Bhigher |
| Earnings | $963Mlower | $1.5Bhigher |
| Employees | 3,244lower | 11,370higher |
| Total assets | $12.9Bhigher | $9Blower |
| Valuation | ||
| P/E | 44.4higher | 21.7lower |
| P/S | 8.6higher | 5.9lower |
| P/B | — | 5.6 |
| Dividend yield | — | 1.03% |
| Profitability | ||
| Operating margin | 28.6%lower | 33.4%higher |
| Balance sheet | ||
| Net assets | $5.8Blower | $6.6Bhigher |
| Total liabilities | $7Bhigher | $2.4Blower |
| Total debt | $5.3Bhigher | $659.4Mlower |
| Cash on hand | $1.7Bhigher | $1.5Blower |
| Price change | ||
| Today | +0.76%higher | -0.14%lower |
| 1 year | +70.1%higher | -3.26%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
Genmab only (1)
- Louis Bacon0.3%
ResMed only (1)
- François Rochon2.8%
Percentages are each holding's share of that investor's reported portfolio. Who owns GMAB · Who owns RMD
More on Genmab
Further comparisons
Genmab against its closest peers
ResMed against its closest peers
Learn
Questions and answers
Which is bigger, Genmab or ResMed?
By market value, ResMed is the larger: $33.5B against $32B for Genmab. By revenue in its latest fiscal year, ResMed is the larger: $5.7B against $3.7B for Genmab.
Which has the higher P/E ratio?
Genmab: 44.4, against 21.7 for ResMed. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.
Which has the higher operating margin?
ResMed: 33.4%, against 28.6% for Genmab. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has more debt?
Genmab: $5.3B, against $659.4M for ResMed. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both Genmab and ResMed?
None of the tracked superinvestors holds both in their latest 13F filing. 1 holds Genmab and 1 holds ResMed.
Cite this page
Funkfolio, “Genmab vs ResMed”, data as of 18 November 2026. https://funkfolio.com/compare/gmab-vs-rmd
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.